The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 5, 2007, Pages 665-677

  Cavusoglu, Yuksel ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Dobutamine; Heart failure; Levosimendan

Indexed keywords

AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; DRUG METABOLITE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; OR 1855; PHOSPHODIESTERASE III; PIMOBENDAN; PLACEBO; SPIRONOLACTONE; UNCLASSIFIED DRUG; VASODILATOR AGENT; CALCIUM CHANNEL; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOSPITAL PATIENT; HUMAN; HYPOTENSION; LOW DRUG DOSE; LUNG CAPILLARY PRESSURE; MONOTHERAPY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PATIENT CARE; PRACTICE GUIDELINE; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; TACHYCARDIA; TACHYPHYLAXIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VASODILATATION; VOMITING; AGED; BIOAVAILABILITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ECONOMICS; EXPERT WITNESS; HALF LIFE TIME; HOSPITALIZATION; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

AGED; BIOLOGICAL AVAILABILITY; CALCIUM CHANNELS; CARDIOTONIC AGENTS; DOBUTAMINE; EXPERT TESTIMONY; HALF-LIFE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; HYDRAZONES; PROGNOSIS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 34047204088     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.5.665     Document Type: Review

References (94)

1. BLEUMINK GS, KNETSCH AM, STURKENBOOM MC et al.: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur. Heart. J. (2004) 25:1614-1619.
2. MCCULLOUGH PA, PHILBIN EF, SPERTUS JA et al.: Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J. Am. Coll. Cardiol. (2002) 39:60-69.
3. NIEMINEN MS, BOHM M, COWIE MR et al.: Guidelines on the diagnosis and treatment of acute heart failure. Eur. Heart. J. (2005) 26:384-416.
4. HO KK, PINSKY JL, KANNEL WB, LEVY D: The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. (1993) 22(Suppl. 4):6A-13A.
5. LLOYD-JONES DM, LARSON MG, LEIP EP et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 106:3068-3072.
6. AMERICAN HEART ASSOCIATION: Heart disease and stroke statistics - 2006 update. American Heart Association, Dallas, Texas (2006).
7. HUNT SA, ABRAHAM WT, CHIN MH et al.: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation (2005) 112:154-235.
8. SWEDBERG K, CLELAND J, DARGIE H et al.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. (2005) 26:1115-1140.
9. JESSUP M, BROZENA S: Heart failure. N. Engl. J. Med. (2003) 348:2007-2018.
10. THE STUDY GROUP ON DIAGNOSIS OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY: Increasing the awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur. J. Heart. Fail. (1999) 1:139-144.
11. GARY R, YUSUF S, FOR THE COLLABORATIVE GROUP ON ACE INHIBITOR TRIALS: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA (1995) 273:1450-1456.
12. BROPHY JM, JOSEPH L, ROULEAU JL: Beta-blockers in congestive heart failure. Ann. Intern. Med. (2001) 134:550-560.
13. PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. (1999) 341:709-707.
14. THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. (1997) 336:525-533.
15. CLELAND JG, DAUBERT JC, ERDMANN E et al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. (2005) 352:1539-1549.
16. KADISH A, DYER A, DAUBERT JP et al.: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med. (2004) 350:2151-2158.
17. BARDY GH, LEE KL, MARK DB et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. (2005) 352:225-237.
18. PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (Vasodilatation in the Management of Acute CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 287:1531-1540.
19. SACKNER-BERNSTEIN JD, KOWALSKI M, FOX M, AARONSON KD: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA (2005) 293:1900-1905.
20. SACKNER-BERNSTEIN JD, SKOPICKI HA, AARONSON KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation (2005) 111:1487-1491.
21. MAISEL AS, WRIGHT CM, CARTER SM et al.: Tachyphylaxis with amrinone therapy: association with sequestration and down-regulation of lymphocyte beta-adrenergic receptors. Ann. Intern. Med. (1989) 110:195-201.
22. CUFFE MS, CALIFF RM, ADAMS KF et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 287:1541-1547.
23. PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. PROMISE Study Research Group. N. Engl. J. Med. (1991) 325:1468-1475.
24. LEIER CV, HEBAN PT, HUSS P et al.: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation (1978) 58:466-475.
25. ROBIE NW, GOLDBERG LI: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine. Am. Heart. J. (1975) 90:340-345.
26. LEIER CV, BINKLEY PF: Parenteral inotropic support for advanced congestive heart failure. Pro. Cardiovasc. Dis. (1998) 41:207-224.
27. HASTILLO A, TAYLOR DO, HESS ML: Specific positive inotropic agents. In: Cardiovascular Drug Therapy, 2nd edn. Messerli FH (Ed.), WB Saunders Company, Philadelphia (1996):1151-1161.
28. LIANG CS, SHERMAN LG, DOHERTY JM et al.: Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation (1984) 69:113-119.
29. KRELL MJ, KLINE EM, BATES ER et al.: Intermittent, ambulatory dobutamine infusion in severe heart failure. Am. Heart. J. (1986) 112:787-791.
30. O'CONNOR CM, GATTIS WA, URETSKY BF et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insight from the Flolan International Randomized Survival Trial (FIRST). Am. Heart. J. (1999) 138:78-76.
31. KATZ SD, KUBO SH, JESSUP M et al.: A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am. Heart. J. (1992) 123:95-103.
32. LUBSEN J, JUST H, HJALMARSSON AL et al.: Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart (1996) 76:223-231.
33. SLAWSKY MT, COLUCCI WS, GOTTLIEB SS et al.: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation (2000) 102:2222-2227.
34. NIEMINEN MS, AKKILA J, HASENFUSS G et al.: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol. (2000) 36:1903-1912.
35. MICHAELS AD, MCKEOWN B, KOSTAL M et al.: Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation (2005) 111:1504-1509.
36. UKKONEN H, SARASTE M, AKKILA J et al.: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin. Pharmacol. Ther. (2000) 68:522-531.
37. LEHTONEN LA: Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin. Investig. Drugs (2001) 10:955-970.
38. FIGGITT DP, GILLES PS, GOA KL: Levosimendan. Drugs (2001) 61:613-627.
39. COLUCCI WS, WRIGHT RF, BRAUNWALD E: New positive agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N. Engl. J. Med. (1986) 314:290-299.
40. ERHARDT LR: Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure? Ital. Heart. J. (2003) 4(Suppl. 2):27S-33S.
41. HAIKALA H, NISSINEN E, ETEMADZADEH E et al.: Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. Pharmacol. (1995) 25:794-801.
42. + channel in rat arterial myocytes. Eur. J. Pharmacol. (1997) 333:249-259.
43. LILLEBERG J, NIEMINEN M, AKKILA J et al.: Effects of a new calcium sensitiser, levosimendan, on heamodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur. Heart. J. (1998) 19:660-668.
44. GRUHN N, NIELSEN-KUDSK JE, THEILGAARD S et al.: Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J. Cardiovasc. Pharmacol. (1998) 31:741-749.
45. BOWMAN P, HAIKALA H, PAUL RJ: Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J. Pharmacol. Exp. Ther. (1999) 288:316-325.
46. PAGEL PS, HETTRICK DA, WARLTIER DC: Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br. J. Pharmacol. (1996) 119:609-615.
47. KERSTEN JR, MONTGOMERY MW, PAGEL PS et al.: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth. Analg. (2000) 90:5-11.
48. JAMALI IN, KERSTEN JR, PAGEL PS et al.: Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth. Analg. (1997) 85:23-29.
49. LEPRAN I, POLLESOLLO P, VAJDA S, VARRO A, PAPP JG: Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. J. Cardiovasc. Pharmacol. (2006) 48:148-152.
50. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ. Res. (1995) 77:107-113.
51. TOIVONEN L, VIITASALO M, SUNDBERG S et al.: Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J. Cardiovasc. Pharmacol. (2000) 35:664-669.
52. ADAMOPOULOS S, PARISSIS JT, ILIODROMITIS EK et al.: Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated heart failure. Am. J. Cardiol. (2006) 98:102-106.
53. PARISSIS JT, ADAMOPOULOS S, ANTONIADES C et al.: Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am. J. Cardiol. (2004) 93:1309-1312.
54. PARISSIS JT, ADAMOPOULOS S, FARMAKIS D et al.: Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. (2006) 92:1768-1772.
55. TRIKAS A, ANTONIADES C, LATSIOS G et al.: Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur. J. Heart. Fail. (2006) 8:804-809.
56. SANDELL EP, HAYHA M, ANTILA S et al.: Pharmacokinetics of levosimendan in healthy volunteers and in patients with congestive heart failure. J. Cardiovasc. Pharmacol. (1995) 26(Suppl.):S57-S62.
57. TAKAHASHI R, TALUKDER MA, ENDOH M et al.: Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur. J. Pharmacol. (2000) 400:103-112.
58. PAGEL PS, HARKINS CP, HETTRICK DA et al.: Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology (1994) 81:974-987.
59. TODAKA K, WANG J, YI GH et al.: Effects of levosimendan on myocardial contractility and oxygen consumption. J. Pharmacol. Exp. Ther. (1996) 279:120-127.
60. 2+] 'I' in guinea-pig isolated ventricular myocytes. Eur. J. Pharmacol. (1997) 339:97-100.
61. PAGEL PS, MCGOUGH MF, HETTRICK DA et al.: Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J. Cardiovasc. Pharmacol. (1997) 29:563-573.
62. JANSSEN PM, DATZ N, ZEITZ O, HASENFUSS G: Levosimendan improves diastolic and systolic function in failing human myocardium. Eur. J. Pharmacol. (2000) 404:191-199.
63. PARISSIS J, PANOU F, FARMAKIS D et al.: Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am. J. Cardiol. (2005) 96:423-426.
64. DU TOIT EF, MULLER CA, MCCARTHY J, OPIE LH : Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J. Pharmacol. Exp. Ther. (1999) 290:505-514.
65. GROSS R, STRAIN J, GREENBERG M et al.: Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J. Am. Coll. Cardiol. (1986) 7:1107-1113.
66. PACOLD I, KLEINMAN B, GUNNAR R et al.: Effects of low-dose dobutamine on coronary hemodynamics, myocardial metabolism and anginal threshold in patients with coronary artery disease. Circulation (1983) 68:1044-1050.
67. SONNTAG S, SUNDBERG S, LEHTONEN LA, KLEBER FX: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J. Am. Coll. Cardiol. (2004) 43:2177-2182.
68. GARCIA-GONZALEZ MJ, DOMINGUEZ-RODRIGUEZ A, FERRER-HITA JJ, ABREU-GONZALEZ P, MUNOZ MB: Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur. J. Heart. Fail. (2006) 8:723-728.
69. DU TOIT E, HOFMANN D, MCCARTHY J, PINEDA C: Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart (2001) 86:81-87.
70. TASSANI P, SCHAD H, HEIMISCH W et al.: Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc. Drugs. Ther. (2002) 16:435-441.
71. TOLLER WG, STRANZ C: Levosimendan, a new inotropic and vasodilator agent. Anesthesiology (2006) 104:556-569.
72. MOISEYEV VS, PODER P, ANDREJEVS N et al.: Safety and efficacy of a novel calcium sensitizer, levosimendan in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart. J. (2002) 23:1422-1432.
73. METRA M, NODARI S, D'ALOIA A et al.: Beta blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. (2002) 40:1248-1258.
74. LEHTONEN L, SUNDBERG S: The contractility enhancing effect of the calcium sensitizer levosimendan is not attenuated by carvedilol in healthy subjects. Eur. J. Clin. Pharmacol. (2002) 58:449-452.
75. FOLLATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet (2002) 360:196-202.
76. MORELLI A, TEBOUL JL, MAGGIORE SM et al.: Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit. Care. Med. (2006) 34:2287-2293.
77. PARISSIS JT, PARASKEVAIDIS I, BISTOLA V et al.: Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am. J. Cardiol. (2006) 98:1489-1492.
78. KERBAUL F, RONDELET B, DEMESTER JP et al.: Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit. Care. Med. (2006) 34:2814-2819.
79. MORELLI A, DE CASTRO S, TEBOUL JL et al.: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. (2005) 31:638-644.
80. KYRZOPOULOS S, ADAMOPOULOS S, PARISSIS JT et al.: Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int. J. Cardiol. (2005) 99:409-413.
81. MUELLER T, GEGENHUBER A, HALTMAYER M: Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. Int. J. Cardiol. (2005) 104:355-356.
82. MCLEAN AS, HUANG SJ, NALOS M, TING I: Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J. Cardiovasc. Pharmacol. (2005) 46:830-835.
83. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompanseted heart failure in comparison with dobutamine. Eur. J. Heart. Fail. (2005) 7:882-887.
84. GIANNAKOULAS G, GIANNOGLOU G, VASSILIKOS V et al.: Clinical significance of acute neurohormonal response after levosimendan treatment. Am. J. Cardiol. (2006) 98:1123-1124.
85. PARISSIS J, FARMAKIS D, BISTOLA V, ADAMOPOULOS S, KREMASTINOS D: Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients. Am. J. Cardiol. (2007) 99:146-147.
86. MEBAZAA A, COHEN-SOLAL A, KLEBER F et al.: The SURVIVE trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. In: American Heart Asssociation Scientific Sessions 2005; November 13-16, 2005, Dallas, Texas. Late Breaking Clinical Trials II. Circulation (2005) 112: 3364.
87. CLELAND JG, FREEMANTLE N, COLETTA AP, CLARK AL: Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart. Fail. (2006) 8:105-110.
88. MCGOUGH MF, PAGEL PS, LOWE D et al.: Levosimendan potentiates the inotropic actions of dopamine in conscious dogs. J. Cardiovasc. Pharmacol. (1996) 28:36-47.
89. CAVUSOGLU Y, BEYAZTAS A, ENTOK E et al.: Additive improvement of systolic and diastolic functions by the concomitant administration of levosimendan and dobutamine in left ventricular dysfunction: a radionuclide ventriculographic study. In: American Heart Asssociation Scientific Sessions 2006; November 12-15, 2006, Chicago, Illinois. Circulation (2006) 114(18) (Suppl.):2946.
90. NANAS JN, PAPAZOGLOU PP, TERROVITIS JV et al.: Haemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am. J. Cardiol. (2004) 94:1329-1332.
91. NANAS JN, PAPAZOGLOU PP, TSAGALOU EP et al: Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am. J. Cardiol. (2005) 95:768-771.
92. DELLE KARTH G, BUBERL A, GEPPERT A et al.: Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta. Anaesthesiol. Scand. (2003) 47:1251-1256.
93. DE LUCA L, COLUCCI WS, NIEMINEN MS et al.: Evidence-based use of levosimendan in different clinical setting. Eur. Heart. J. (2006) 27:1908-1920.
94. FLEVARI P, PARISSIS JT, LEFTHERIOTIS D, PANOU F, KOUREA K, KREMASTINOS DT: Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am. J. Cardiol. (2006) 98:1641-1645.